Phase 2: Introduce AOD 9604 (weeks 5-8) Once tirzepatide is tolerated at the initial dose, add AOD 9604 at 250mcg daily
Again, evidence is primarily animal-based, not FDA approved
Compare realistic benefits, limitations, safety, and total cost before acting
While AOD 9604 shows promise for fat loss and muscle preservation, the results vary between individuals
Rubino DM, et al
Zara Cosentino, commenting on the committee's composition, said that while disclosure requirements represent a positive transparency measure, the situation creates a structural problem "especially when the people who stand to gain from growing access are the ones making the decision." Attorneys at Orrick, analyzing the committee before the meeting, concluded that the most probable outcome was that PCAC would recommend inclusion for some or all of the seven peptides calling it "a significant departure from prior PCAC precedent." Their prediction was accurate to the letter